margetuximab (Margenza) Report issue

Biologics mAb Approved FDA Fast Track FDA
AACT ChEMBL

Active Ingredient History

NOW
  • Now
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

margetuximab | mgah22

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (1)


 

Breast Neoplasms (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Cholangiocarcinoma (Phase 1)

Esophageal Neoplasms (Phase 2/Phase 3)

Hematologic Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stomach Neoplasms (Phase 2/Phase 3)

Uterine Cervical Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue